About Cellf
Cellf is a Healthcare company based in Mumbai (India) founded in 2006. It develops innovative cellular therapies for oncology and regenerative medicine. It operates on a B2B model. Its Indian entity Cellf Therapeutics Private Limited reported revenue of ₹6.1 Lakh. Its focus areas include Biotechnology, Oncology and Cellular Therapies. Similar companies include Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte and 4 more; 8 of its 9 listed similar companies have raised funding.
Company details
Cellf develops innovative cellular therapies for oncology and regenerative medicine, focusing on providing healthcare solutions, advancing biotech innovations, oncology, and cellular therapies. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets. It continues to evolve, meeting industry challenges with strategic approaches.
- Headquarters Mumbai, India
- Employees 1
- SectorsHealthcare
- Website cellf.in
- Legal Name Cellf Therapeutics Private Limited
- Date of Incorporation 16 Jun, 2020
- Jurisdiction Bangalore, Karnataka, India
- Annual Revenue₹6.1 Lakh
FY 2024 · +920% YoY
- Net Loss-₹20.1 Lakh
FY 2024 · -329% margin
- EBITDA-₹20.1 Lakh
FY 2024 · -329% margin
- Employee Count1
Associated legal entities of Cellf
Cellf operates through Cellf Therapeutics Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Cellf Therapeutics Private Limited CIN U73100KA2020PTC134938 | Active | 16 Jun 2020 | Bangalore, Karnataka | ₹0.1 Cr | – | 4 | View details |
Board of directors of Cellf Therapeutics Private Limited (Cellf)
Cellf Therapeutics Private Limited is the primary company behind Cellf. The board of Cellf Therapeutics Private Limited currently have 4 directors; the longest-serving is Vishal Uchila Shishir, appointed in 2020. 3 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Vishal Uchila Shishir DIN 07061182 | Director | 16 Jun 2020 | 6 yrs 4 mo | Cellf Therapeutics Private Limited |
| Vishwas Uchila Shishir DIN 08241526 | Director | 16 Dec 2024 | 1 yr 10 mo | Cellf Therapeutics Private Limited |
| Vivek Sharma DIN 08307569 | Additional Director | 05 Jun 2025 | 1 yr 4 mo | Cellf Therapeutics Private Limited |
| Ashish Dolatrai Desai DIN 11178274 | Additional Director | 05 Jun 2025 | 1 yr 4 mo | Cellf Therapeutics Private Limited |
Financials of Cellf
Figures of Cellf Therapeutics Private Limited, the primary company behind Cellf, for FY 2024. Revenue was ₹6.1 Lakh (+920% year on year). Net loss was -₹20.1 Lakh (-329% margin). EBITDA was -₹20.1 Lakh (-329% margin).
- ₹6.1 LakhRevenue · FY 2024 · +920% YoY
- -₹20.1 LakhNet loss · -329% margin
- -₹20.1 LakhEBITDA · -329% margin
- ₹33.5 LakhPaid-up capital
Balance sheet, profit and loss, cash flow and ratios of Cellf Therapeutics Private Limited are on its company page.
Detailed financial statements for Cellf
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to Cellf
Cellf has 9 listed similar companies in our database, 8 of them funded. They include Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.13M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed similar companies of Cellf
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cell Therapy
10 companies that operate in the same segment as Cellf (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 253 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cellf
Cellf was founded in 2006.
Cellf is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Cellf has 1 employees.
The primary company behind Cellf, Cellf Therapeutics Private Limited, reported revenue of ₹6.1 Lakh for FY 2024, up 920% year on year.
Cellf develops innovative cellular therapies for oncology and regenerative medicine, focusing on providing healthcare solutions, advancing biotech innovations, oncology, and cellular therapies. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets. It continues to evolve, meeting industry challenges with strategic approaches.
Cellf's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Cellf operates through Cellf Therapeutics Private Limited.
The legal entities of Cellf currently have 4 directors, including Vishal Uchila Shishir, Vishwas Uchila Shishir, Vivek Sharma and others.